ArticleAmerican journal of translational research2021
The therapeutic effect of the digestive endoscopy tunneling technique on upper gastrointestinal muscularis propria tumors.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the therapeutic effect of digestive endoscopy tunneling technology on upper gastrointestinal muscularis propria tumors.
methodsA total of 120 patients with upper gastrointestinal tumors in the muscularis propria treated in our hospital in the past two years were recruited as the study cohort. They were treated using the digestive endoscopic tunneling technique, specifically, endoscopic submucosal tunneling tumor resections, and their clinical data, surgical conditions, pathological results, incidences of complications (CR), and anxiety scores were recorded. A postoperative follow-up was conducted on the patients.
resultsA total of 122 tumors were removed from 120 patients, including two patients who had two tumors each. The largest diameter among the tumors was 4.2 cm, and the average diameter was (2.01±1.56) cm. There were 86 tumors located in the superficial layer of the muscularis propria and 36 pieces in the deep layer. No significant differences were found in the patients' clinical data (P > 0.05). The 120 patients all successfully completed their operations. The operation times ranged between 26 min and 158 min. The en bloc resection rate was 95.8%, and the average postoperative hospital stay was 3.8 days. The pathological diagnoses showed that there were 72 leiomyomas, accounting for 59.0% of the total, and 44 stromal tumors, accounting for 36.1%. There were 2 glomus tumor cases, accounting for 1.6%, and 4 nerve sheath tumor cases, accounting for 3.3%. No patient had delayed gastrointestinal bleeding or mucosal perforations. The probability of subcutaneous emphysema and pneumothorax was 1.7%, the probability of pneumoperitoneum was 0.8%, the probability of retrosternal pain was 10.0%, and the total incidence of CR was 14.2%. No tumor recurrence or residual phenomenon was found at the 3, 6, or 12 month follow ups after the treatment, and the patients' satisfaction rate was as high as 98.3%. Their anxiety scores also decreased significantly over time (P < 0.001).
conclusionDigestive endoscopy tunnel technology can effectively improve the surgical success rate of patients with upper gastrointestinal muscularis propria tumors, reduce the probability of CR, and reduce patients' psychological pressure. It has significant effects in the treatment of upper gastrointestinal muscularis propria tumors and should be widely applied in clinical practice.
Indexed as
Identifiers
34650740PMC8507020W3207136660What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.